Tofacitinib (CP-690550)

Licensed by Pfizer Catalog No.S2789 Synonyms: Tasocitinib

For research use only.

Tofacitinib (CP-690550,Tasocitinib) is a novel inhibitor of JAK3 with IC50 of 1 nM in cell-free assays, 20- to 100-fold less potent against JAK2 and JAK1. Tofacitinib inhibits the expression of antiapoptotic BCL-A1 and BCL-XL in human plasmacytoid dendritic cells (PDC) and induced PDC apoptosis.

Tofacitinib (CP-690550) Chemical Structure

CAS No. 477600-75-2

Selleck's Tofacitinib (CP-690550) has been cited by 136 publications

Purity & Quality Control

Choose Selective JAK Inhibitors

Other JAK Products

Biological Activity

Description Tofacitinib (CP-690550,Tasocitinib) is a novel inhibitor of JAK3 with IC50 of 1 nM in cell-free assays, 20- to 100-fold less potent against JAK2 and JAK1. Tofacitinib inhibits the expression of antiapoptotic BCL-A1 and BCL-XL in human plasmacytoid dendritic cells (PDC) and induced PDC apoptosis.
Targets
JAK3 [1]
(Cell-free assay)
JAK2 [1]
(Cell-free assay)
JAK1 [1]
(Cell-free assay)
1 nM 20 nM 112 nM
In vitro

CP-690550 is a specific, orally inhibitor of JAK3, it is 20- to 100-fold less potent for JAK2 and JAK1 with IC50 of 20 nM and 112 nM, respectively. CP-690550 doesn't have potent activity against 30 other kinases (all median IC50 > 3000 nM). CP-690,550 inhibits IL-2–induced proliferation with 30-fold greater potency than its effects on GM-CSF–induced proliferation. [1] CP-690550 effectively inhibits a murine mixed lymphocyte reaction (MLR) (IC50 = 91 nM). [2] CP-690550 potently inhibits IL-4 induced upregulation of CD23 (IC50=57 nM) and class II major histocompatibility complex (MHCII) expression (IC50=71 nM) on murine B cells. [3] A recent research indicates low dose of CP-690550 accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
T cells M1P5cGZ2dmO2aX;uJGF{e2G7 MmnxNE4yNzBwMz:xJO69VQ>? M3TXcVI1KGh? NVj5emt[\Gm|coXweJMh|rOlLXPoZYlvKGO7dH;rbY5mKHOrZ37hcIlv\w>? MlryQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|OEOyOFEoRjJzM{izNlQyRC:jPh?=
CD4+ T  MYPGeY5kfGmxbjDBd5NigQ>? M3njXVExOCCwTR?= M1znb|I1NzR6IHi= MXzhZpJw\2G2ZYOgR2Q{NWmwZIXj[YQheGixc4Doc5J6dGG2aX;uJI9nKFOWQWTz M2f2XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEi0OVgxLz5{MUi4OFU5ODxxYU6=
CD4+ T  M1XQSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTxNVAxNzVyMDDuUS=> NX64NXk4PDhiaB?= NUnUeHkxcW6qaXLpeJMh[W62aT3DSFMucW6mdXPl[EBETDRtwrDUJINmdGxicILvcIln\XKjdHnvci=> Mo\CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6OES1PFAoRjJzOEi0OVgxRC:jPh?=
CD4+ T  MV7GeY5kfGmxbjDBd5NigQ>? NH;UUoUzOC9zMECvOVAxKG6P MoDTOFghcA>? MkTqbY5pcWKrdIOgeIhmKGyndnXsd{Bw\iBiSVytOEwhUU[QLd8zMEBKVC1zN1GgZY5lKEmOLUKy Mn\wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6OES1PFAoRjJzOEi0OVgxRC:jPh?=
Sf9 M3ftV2Z2dmO2aX;uJIF{e2G7 M121TVMxKG2rboO= NVvnWlNyUW6qaXLpeIlwdiCxZjDoeY1idiCJU2St[pV{\WRiSlHLN{Bk[XSjbIn0bYMh\G:vYXnuJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3cz3pcoZm[3SnZDDT[lkh[2WubIOgeZNqdmdicH;sfYdtfXSjbXnjJIFkcWRvdInyc5NqdmViYYOgd5Vje3S{YYTlJIFnfGW{IEOwJI1qdnNiYomgSWxKW0FuIFvpJF0hOC5yMEC0JO69VS5? MnfjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4Nki0PFQoRjJ|Nk[4OFg1RC:jPh?=
Sf9 MVPGeY5kfGmxbjDhd5NigQ>? M{j4R|kxKG2rboO= MlnKTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCQLYTldo1qdmGuIFfTWE11[WepZXSgTmFMOyCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJJV{cW6pIFLpc5Rqdi2OQz3FVWVFTVCHR1TZSmVYVEViYYOgd5Vje3S{YYTlJIFnfGW{IEmwJI1qdnNiYomgWHIuTlKHVDDhd5NigSxiSVO1NEA:KDBwMECwOkDPxE1w MoriQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyOEe3OVAoRjJ{MEi3O|UxRC:jPh?=
Sf9 MXvGeY5kfGmxbjDhd5NigQ>? MUWzNEBucW6| NV6xfG1pUW6qaXLpeIlwdiCxZjDoeY1idiCJU2St[pV{\WRiSlHLNUBk[XSjbIn0bYMh\G:vYXnuJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3cz3pcoZm[3SnZDDT[lkh[2WubIOgeZNqdmdicH;sfYdtfXSjbXnjJIFkcWRvdInyc5NqdmViYYOgd5Vje3S{YYTlJIFnfGW{IEOwJI1qdnNiYomgSWxKW0FuIFvpJF0hOC5yMEC3JO69VS5? MnPzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4Nki0PFQoRjJ|Nk[4OFg1RC:jPh?=
Sf9 NHXae2ZHfW6ldHnvckBie3OjeR?= NVu1T5p1OzBibXnudy=> MmfuTY5pcWKrdHnvckBw\iCqdX3hckBIW1RvZoXz[YQhUkGNMjDjZZRidHm2aXOg[I9u[WmwIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2ey2rbn\lZ5Rm\CCVZkmgZ4VtdHNidYPpcocheG:ueXfseZRidWmlIHHjbYQufHm{b4PpcoUh[XNic4Xid5Rz[XSnIHHmeIVzKDNyIH3pcpMh[nliRVzJV2EtKEurIE2gNE4xODB5IN88UU4> MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ4OES4OEc,OjN4Nki0PFQ9N2F-
Sf9 Mo\wSpVv[3Srb36gZZN{[Xl? M{[zdmlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiR2PUMZRi\2enZDDKTFEh\G:vYXnuJEg4QDVidH:xNVI2MSCxZjDKRWs{KGW6cILld5Nm\CCrbjDpcpNm[3RiU3[5JINmdGy|IHL5JGVNUVODLDDJR|UxKD1iMD6wNFEh|ryPLh?= MnzNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTR3OUOxPFIoRjF2NUmzNVgzRC:jPh?=
Sf9 MYHGeY5kfGmxbjDhd5NigQ>? NFnhV49KdmirYnn0bY9vKG:oIFfTWE11[WepZXSgbJVu[W5iSlHLN{Bk[XSjbIn0bYMh\G:vYXnuJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiYomgSWxKW0FuIFnDOVAhRSByLkCwNUDPxE1w NWf2dpNmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxNFU4OTFpPkKxNVA2PzFzPD;hQi=>
Sf9 NUPBNVVPTnWwY4Tpc44h[XO|YYm= NUDDOY5GQTBibXnudy=> MWDJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KE5vdHXycYlv[WxiR2PUMZRi\2enZDDKRWsyKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgeZNqdmdiQnnveIlvNUyFLVXRSWRGWEWJRGnGSXdNTSCjczDzeYJ{fHKjdHWgZYZ1\XJiOUCgcYlveyCkeTDUVk1HWkWWIHHzd4F6NCCLQ{WwJF0hOC5yMEOg{txONg>? MmnpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyOEe3OVAoRjJ{MEi3O|UxRC:jPh?=
Sf9 Mn7qSpVv[3Srb36gZZN{[Xl? MmnVTY5pcWKrdHnvckBw\iCJU2SteIFo\2WmIHj1cYFvKEqDS{OgZ4F1[Wy7dHnjJIRwdWGrbjDlfJBz\XO|ZXSgbY4hW2Z7IHPlcIx{KGK7IFXMTXNCNCCLQ{WwJF0hOC5yMEOzJO69VS5? MkjOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzMEW3NVEoRjJzMUC1O|EyRC:jPh?=
Sf9 MVjGeY5kfGmxbjDhd5NigQ>? MkTUPVAhdWmwcx?= MXTJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KE5vdHXycYlv[WxiR2PUMZRi\2enZDDKRWszKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgeZNqdmdiQnnveIlvNUyFLVXRSWRGWEWJRGnGSXdNTSCjczDzeYJ{fHKjdHWgZYZ1\XJiOUCgcYlveyCkeTDUVk1HWkWWIHHzd4F6NCCLQ{WwJF0hOC5yMESg{txONg>? NYnTXlBjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwPFc4PTBpPkKyNFg4PzVyPD;hQi=>
SF21 NETrR21HfW6ldHnvckBie3OjeR?= M4P0bFExKG2rboO= NVX5XYp3UW6qaXLpeIlwdiCxZjDKRWszKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIGPGNlEh[2WubIOgeZNqdmdiQnnveIlvNUuDSVXUSGtGYVmWVlvEJIF{KHO3YoP0doF1\SCjbnSgX|M{WGejbX3hYWFVWCCrbnP1ZoF1\WRiZn;yJFExKG2rboOgdJJqd3JidH:gd5Vje3S{YYTlJIFl\Gm2aX;uJI1m[XO3cnXkJIFnfGW{IEOwJI1qdnNiYomgWI9x[2:3boSgZY5idHm|aYOsJGlEPTBiPTCwMlAxPCEQvF2u NIX6eGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W0NVY4OCd-MkO1OFE3PzB:L3G+
insect cells NVrqbGROTnWwY4Tpc44h[XO|YYm= M1\vTWlvcGmkaYTpc44hd2ZiR2PUMZRi\2enZDDKZYsyKGW6cILld5Nm\CCrbjDpcpNm[3RiY3XscJMhfXOrbnegO|AhfU1iQWTQMEBKSzVyIE2gNE4xODZzIN88UU4> NFzXemc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG1OVYxPSd-MkGxOVU3ODV:L3G+
insect cells NVjWO5g6TnWwY4Tpc44h[XO|YYm= NWLoVG9WUW6qaXLpeIlwdiCxZjDHV3QufGGpZ3XkJGpiczNiZYjwdoV{e2WmIHnuJIlve2WldDDj[YxteyC3c3nu[{AyQCC3TTDBWHAtKEmFNUCgQUAxNjByODFOwG0v NYC5Vm85RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxOVU3ODVpPkKxNVU2PjB3PD;hQi=>
T-cells M4O4RWZ2dmO2aX;uJIF{e2G7 NWnQfYl6PzJiaILz NGezPHhKdmirYnn0bY9vKG:oIFnMNk1qdmS3Y3XkJJBzd2yrZnXyZZRqd25ib3[gbJVu[W5iVDDj[YxteyCjc4Pld5Nm\CCjczDbN2hefGi7bXnkbY5mKGmwY3;ydI9z[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IIPjbY51cWyuYYTpc44h[2:3boTpcoctKEmFNUCgQUAxNjBzMTFOwG0v MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPDV7M{G4Nkc,OTR3OUOxPFI9N2F-
insect cells NHjwVlJHfW6ldHnvckBie3OjeR?= M3;KO2lvcGmkaYTpc44hd2ZiR2PUMZRi\2enZDDKZYszKGW6cILld5Nm\CCrbjDpcpNm[3RiY3XscJMhfXOrbnegNlAhfU1iQWTQMEBKSzVyIE2gNE4xOTJizszNMi=> NFSxTmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG1OVYxPSd-MkGxOVU3ODV:L3G+
MO7 NY\MNVliTnWwY4Tpc44h[XO|YYm= MXjJcohq[mm2aX;uJI9nKEqja{OtcYVlcWG2ZXSgTWwyPS2rbnT1Z4VlKFO2YYS1JJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDNU|ch[2WubIOgZpkh[2WubD3iZZNm\CCjc4PhfUwhUUN3MDC9JFAvODJ2IN88UU4> MnjUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzNUW2NFUoRjJzMUW1OlA2RC:jPh?=
Ba/F3 M2TB[WZ2dmO2aX;uJIF{e2G7 M3zDWlYxKG2rboO= MkLITY5pcWKrdHnvckBw\iCWRVyt[pV{\WRiSlHLNUBmgHC{ZYPz[YQhcW5iQnGvSlMh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDTWGFVPSCyaH;zdIhwenmuYYTpc44h[W[2ZYKgOlAhdWmwczDifUBCdHCqYWPjdoVmdiCjc4PhfUwhUUN3MDC9JFAvODJ4IN88UU4> M1uyW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEi3O|UxLz5{MkC4O|c2ODxxYU6=
T-cells MUfGeY5kfGmxbjDhd5NigQ>? MYjJcohq[mm2aX;uJI9nKEqDS{OvNUBqdiCqdX3hckBVKGOnbHzzJIV5eHKnc4PpcochS0R|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiSVyyMZN1cW23bHH0[YQhW1SDVEXhJJBpd3OyaH;yfYxifGmxbjygTWM2OCB;IECuNFI5KM7:TT6= NGjLbWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W0NFY1QCd-MkO1OFA3PDh:L3G+
PBMC MVPGeY5kfGmxbjDhd5NigQ>? MXrJcohq[mm2aX;uJGlNNTdvaX7kZ5Vm\CCVVFHUOUBxcG:|cHjvdplt[XSrb36gbY4hcHWvYX6gVGJOSyClZXzsd{BjgSCobH;3JIN6fG:vZYTyfUwhUUN3MDC9JFAvODN7IN88UU4> MonOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7Mke0NlMoRjJ4OUK3OFI{RC:jPh?=
TF1 NUj2cVI{TnWwY4Tpc44h[XO|YYm= NWfIcGs5OjBibXnudy=> MWnJcohq[mm2aX;uJI9nKEqDS{GgbY4hcHWvYX6gWGYyKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gTWw3NWmwZIXj[YQhW1SDVEOgdIhwe3Cqb4L5cIF1cW:wIHnuZ5Vj[XSnZDDmc5IhOjBibXnud{Bnd2yub4fl[EBjgSCLTE[gZ4hidGynbnflJIZweiB|MDDtbY5{KGmwIIDy[ZNmdmOnIH;mJJdpd2ynIHLsc49lNCCHQ{WwJF0hOC5yNEOg{txONg>? M{XkfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkW5NlE1Lz5{M{[1PVIyPDxxYU6=
TF1 NET4OHdHfW6ldHnvckBie3OjeR?= MY\Jcohq[mm2aX;uJI9nKEqDS{GgbY4hcHWvYX6gWGYyKGOnbHzzJIF{e2W|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJGlNPi2|dHnteYxifGWmIGPURXQ{KHCqb4PwbI9zgWyjdHnvckBjgSCDbIDoZXNkemWnbjDhd5NigSxiSV7IJF0hOC5yNEWg{txONg>? M2X6O|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{eyOlU{Lz5{NkO3NlY2OzxxYU6=
CTLL MXrGeY5kfGmxbjDhd5NigQ>? NX\OT|g6UW6qaXLpeIlwdiCxZjDKZYs{NW2nZHnheIVlKEmOMj3pcoR2[2WmIGP0ZZQ2KHCqb4PwbI9zgWyjdHnvckBqdiCvb4Xz[UBEXEyOIHPlcIx{KGK7IHPlcIwu[mG|ZXSgZZN{[XluIFnDOVAhRSByLkC0PEDPxE1w M2[0flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUW1OlA2Lz5{MUG1OVYxPTxxYU6=
Sf9 NGDYV4dHfW6ldHnvckBie3OjeR?= MoftPVAhdWmwcx?= MlTwTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCQLYTldo1qdmGuIFfTWE11[WepZXSgWHlMOiCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJJV{cW6pIFLpc5Rqdi2OQz3FVWVFTVCHR1TZSmVYVEViYYOgd5Vje3S{YYTlJIFnfGW{IEmwJI1qdnNiYomgWHIuTlKHVDDhd5NigSxiSVO1NEA:KDBwMEWyJO69VS5? NVzzcVhJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwPFc4PTBpPkKyNFg4PzVyPD;hQi=>
TF1 M2WyemZ2dmO2aX;uJIF{e2G7 MV;Jcohq[mm2aX;uJI9nKEqDS{GgbY4hcHWvYX6gWGYyKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gTWwzNWmwZIXj[YQhW1SDVEOgdIhwe3Cqb4L5cIF1cW:wLDDFR|UxKD1iMD6wOVMh|ryPLh?= MoLCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3OUG0NFIoRjJ{NUmxOFAzRC:jPh?=
TF1 NXPx[5Q4TnWwY4Tpc44h[XO|YYm= MUGyNEBucW6| NXfOeHE1UW6qaXLpeIlwdiCxZjDKRWsyKGmwIHj1cYFvKFSIMTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEmONj3pcoR2[2WmIGPURXQ{KHCqb4PwbI9zgWyjdHnvckBqdmO3YnH0[YQh\m:{IEKwJI1qdnNicILpc5IhfG9iSVy2MYlv\HWldHnvckBu\WG|dYLl[EBi\nSncjCzNEB1dyB2NTDtbY5{NCCHQ{WwJF0hOC5yNUOg{txONg>? Ml35QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4OUiwPFQoRjJ{Nkm4NFg1RC:jPh?=
TF1 M4ez[mZ2dmO2aX;uJIF{e2G7 MVKyNEBucW6| NXjndXMzUW6qaXLpeIlwdiCxZjDKRWsyKGmwIHj1cYFvKFSIMTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEmONj3pcoR2[2WmIGPURXQ{KHCqb4PwbI9zgWyjdHnvckBqdmO3YnH0[YQh\m:{IEKwJI1qdnNiZn;scI94\WRiYomgTWw3KGOqYXzs[Y5o\SCob4KgN|AhdWmwczygSWM2OCB;IECuNFU{KM7:TT6= MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ3OUKxOEc,OjN4NUmyNVQ9N2F-
Ba/F3 MVrGeY5kfGmxbjDhd5NigQ>? MY[2NEBucW6| M1X4TmlvcGmkaYTpc44hd2ZiVFXMMYZ2e2WmIFrBT|Mh\XiycnXzd4VlKGmwIFLhM2Y{KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gV3RCXDVicHjvd5Bpd3K7bHH0bY9vKGGodHXyJFYxKG2rboOgZpkhSWyyaHHTZ5Jm\W5iYYPzZZktKEmFNUCgQUAxNjB3NDFOwG0v M4P3ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEi3O|UxLz5{MkC4O|c2ODxxYU6=
T-cells MULGeY5kfGmxbjDhd5NigQ>? MmOyTY5pcWKrdHnvckBw\iCjbHzv[4VvcWNiY3XscJMue3SrbYXsZZRm\CCycn;sbYZmemG2aX;uJIlvKG2xbnvlfUBVKGOnbHzzJIJ6KG2reHXkJIx6dXCqb3P5eIUhemWjY4Tpc44hdWW2aH;kMEBKSzVyIE2gNE4xPTdizszNMi=> MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPDV7M{G4Nkc,OTR3OUOxPFI9N2F-
CD34+ NGK0UZlHfW6ldHnvckBie3OjeR?= NXjz[FF3UW6qaXLpeIlwdiCxZjDKRWszKGmwIHj1cYFvKEOGM{SrJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiRWDPMY1m\GmjdHXkJINmdGxicILvcIln\XKjdHnvckwhUUN3MDC9JFAvODdzIN88UU4> M2nYXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUK3OFI{Lz5{NkmyO|QzOzxxYU6=
TF1 M2\YUmZ2dmO2aX;uJIF{e2G7 Mo\XTY5pcWKrdHnvckBw\iCLTEStbY5lfWOnZDDwdo9tcW[ncnH0bY9vKG:oIGTGNUBk\WyuczygTWM2OCB;IECuNFgh|ryPLh?= M4WwPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OUO0OFU4Lz5zNkmzOFQ2PzxxYU6=
T-cells NXT3eHFxTnWwY4Tpc44h[XO|YYm= NXfUe5NCUW6qaXLpeIlwdiCxZjDhcIxw\2WwaXOgZ4VtdHNvc4TpcZVt[XSnZDDwdo9tcW[ncnH0bY9vKGmwIHj1cYFvKFRiY3XscJMh[nlibXn4[YQhdHmvcHjvZ5l1\SC{ZXHjeIlwdiCvZYToc4QtKEmFNUCgQUAxNjB6NzFOwG0v MkXOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTR3OUOxPFIoRjF2NUmzNVgzRC:jPh?=
TF1 MUTGeY5kfGmxbjDhd5NigQ>? M4fEUFIxKG2rboO= MUDJcohq[mm2aX;uJI9nKEqDS{KgbY4hcHWvYX6gWGYyKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gSXBQNWmwZIXj[YQhW1SDVEWgdIhwe3Cqb4L5cIF1cW:wIHnuZ5Vj[XSnZDDmc5IhOjBibXnud{BxemmxcjD0c{BGWE9vaX7keYN1cW:wIH3lZZN2emWmIHHmeIVzKDNyIITvJFQ2KG2rboOsJGVEPTBiPTCwMlA6OyEQvF2u MnrzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4OUiwPFQoRjJ{Nkm4NFg1RC:jPh?=
TF1 MWnGeY5kfGmxbjDhd5NigQ>? NF\ScW0zOCCvaX7z NVLMbI81UW6qaXLpeIlwdiCxZjDKRWszKGmwIHj1cYFvKFSIMTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEWSTz3pcoR2[2WmIGPURXQ2KHCqb4PwbI9zgWyjdHnvckBqdmO3YnH0[YQh\m:{IEKwJI1qdnNiZn;scI94\WRiYomgTWw3KGOqYXzs[Y5o\SCob4KgN|AhdWmwczygSWM2OCB;IECuNFk{KM7:TT6= NYT6RYl2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2OVkzOTRpPkKzOlU6OjF2PD;hQi=>
PBMC MX3GeY5kfGmxbjDhd5NigQ>? MmrVTY5pcWKrdHnvckBw\iCMQVuxJIlvKGi3bXHuJHBDVUNiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBKVC14LXnu[JVk\WRiTVPQNUB{\WO{ZYTpc44tKEmFNUCgQUAxNjB7NTFOwG0v NGS1T4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkmyO|QzOyd-Mk[5Nlc1OjN:L3G+
TF1 NGjCPWdHfW6ldHnvckBie3OjeR?= Mn3YNkBpenN? NWDFV4tvUW6qaXLpeIlwdiCxZjDKRWszKGmwIFfNR3NHNXO2aX31cIF1\WRiaIXtZY4hXEZzIHPlcIx{KGG|c3Xzd4VlKGG|IIP1dJBz\XO|aX;uJI9nKFOWQWS1JJBpd3OyaH;yfYxifGmxbjDwdoVqdmO3YnH0[YQh\m:{IEKgbJJ{KG[xbHzve4VlKGK7IFfNR3NHKHO2aX31cIF1cW:wIH\vdkA2OCCvaX7zJIJ6KE[DQ2OgdoVi\GW{IHHuZYx6e2m|LDDJR|UxKD1iMD6wPVUh|ryPLh?= NF[2dJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GzNFM2QSd-MkexN|A{PTl:L3G+
TF1 NWHNbGtSTnWwY4Tpc44h[XO|YYm= MWrJcohq[mm2aX;uJI9nKEqDS{KgbY4hTVCRLYP0bY12dGG2ZXSgbJVu[W5iVF[xJINmdGy|IHX4dJJme3Orbnegd5Ri[my7IHnueIVoemG2ZXSgZoV1[S2uYXP0ZY1ie2VicnXwc5J1\XJiZ3Xu[UB2dmSncjDjc451em:uIH;mJHNVSVR3IILld5BwdnOnIHXs[Y1mdnS|IHnuJIlvfGW{ZnXyc44hemWpdXzheI9zgSCoYXP0c5IhOSCpZX7lJJBzd22xdHXyJIJ6KG[udX;y[ZNk\W6lZTDhd5NigSxiSVO1NEA:KDBwMUC3JO69VS5? NHXnVlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG1OlE{Pid-MkmxOVYyOzZ:L3G+
Sf9 MXfGeY5kfGmxbjDhd5NigQ>? NWfT[llxUW6qaXLpeIlwdiCxZjDHV3QufGGpZ3XkJIh2dWGwIFrBT|Eh[2G2YXz5eIlkKGSxbXHpckBmgHC{ZYPz[YQhcW5iU3[5JINmdGy|IHL5JGVNUVODLDDJR|UxKD1iMD6xNUDPxE1w MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTFyNUexNUc,OjFzMEW3NVE9N2F-
T-cells MWPGeY5kfGmxbjDhd5NigQ>? MV;Jcohq[mm2aX;uJI9nKGGubH;n[Y5q[yClZXzsd{1{fGmvdXzheIVlKHC{b3zp[oVz[XSrb36gbY4hdW:3c3WgWEBk\WyuczDifUBucXinZDDsfY1xcG:leYTlJJJm[WO2aX;uJI1mfGixZDygTWM2OCB;IECuNVE2KM7:TT6= M4nrW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2NUmzNVgzLz5zNEW5N|E5OjxxYU6=
ME180 NGfmcFlHfW6ldHnvckBie3OjeR?= NVPVV3hXUW6qaXLpeIlwdiCxZjDKRWsyKGmwIFnMOk1{fGmvdXzheIVlKGi3bXHuJG1GOThyIHPlcIx{KGW6cILld5Nqdmdic4ThZox6KGmwdHXndoF1\WRiYnX0ZU1t[WO2YX3hd4UhemWyb4L0[ZIh\2WwZTD1coRmeiClb370do9tKG:oIIPpd{1qdmS3Y3nicIUh\WynbXXueEBjgSCobIXvdoV{[2WwY3WgZZN{[XluIFnDOVAhRSByLkGyOEDPxE1w NG\TSpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG1OlE{Pid-MkmxOVYyOzZ:L3G+
CTLL-2 M175d2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 M3vMWVczKGi{cx?= M1zC[GFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgTWwuOi2|dHnteYxifGWmIH3veZNmKEOWTFytNkBk\WyuczDlfJBz\XO|aX7nJGpCUzFxSlHLN{Bi\nSncjC3NkBpenNiYomgZYxidWG{IHLseYUh[XO|YYmsJGlEPTBiPTCwMlE{OiEQvF2u NWLDUoRSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OlIzOzhpPkG5O|YzOjN6PD;hQi=>
HT2 NGjaOJRHfW6ldHnvckBie3OjeR?= NWfhTIl7UW6qaXLpeIlwdiCxZjDKRWs{KGmwIH3veZNmKEiWMjDj[YxteyCjc4Pld5Nm\CCjczDzeZBxemW|c3nvckBw\iClZXzsJIdzd3e2aDygTWM2OCB;IECuNVU3KM7:TT6= NFK2PJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e3NVE5OCd-Mke3O|EyQDB:L3G+
DND/L12 MV3GeY5kfGmxbjDhd5NigQ>? MUizNEBucW6| NYrXV2lrUW6qaXLpeIlwdiCxZjDKRWs{KGmwIHj1cYFvKESQRD;MNVIh[2WubIOgZYZ1\XJiM{CgcYlveyCkeTDseYNq\mW{YYPlJIF{e2G7IHnuJJBz\XOnbnPlJI9nKGi3bXHuJJNmenWvIHHsZpVucW5uIFnDPVAhRSByLkG2JO69VS5? MlXaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTR3OUOxPFIoRjF2NUmzNVgzRC:jPh?=
T-cells NE\uOY9HfW6ldHnvckBie3OjeR?= M{fybmlvcGmkaYTpc44hd2ZiSlHLNk8yKGmwIHj1cYFvKFRiY3XscJMh\XiycnXzd4lv\yCFREOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDJSm5o[W2vYT3zeIlufWyjdHXkJHNVSVRzIIDoc5NxcG:{eXzheIlwdixiSVO1NEA:KDBwMUeg{txONg>? NXjVdmk3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OFA3PDhpPkKzOVQxPjR6PD;hQi=>
insect MW\GeY5kfGmxbjDhd5NigQ>? MWjJcohq[mm2aX;uJI9nKEeVVD30ZYdo\WRiVInrNkBmgHC{ZYPz[YQhcW5iaX7z[YN1KGOnbHzzJJV{cW6pIEO1JJVOKEGWUDygTWM2OCB;IECuNVc3KM7:TT6= M3\NfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUW1OlA2Lz5{MUG1OVYxPTxxYU6=
Ba/F3 Mk\FSpVv[3Srb36gZZN{[Xl? MUS2NEBucW6| MUXJcohq[mm2aX;uJI9nKFSHTD3meZNm\CCMQVuyJIV5eHKnc4Pl[EBqdiCEYT;GN{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGPURXQ2KHCqb4PwbI9zgWyjdHnvckBi\nSncjC2NEBucW6|IHL5JGFteGijU3Py[YVvKGG|c3H5MEBKSzVyIE2gNE4zPjVizszNMi=> Ml7kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyOEe3OVAoRjJ{MEi3O|UxRC:jPh?=
TF1 NUnuW4QyTnWwY4Tpc44h[XO|YYm= NUfTZlhTUW6qaXLpeIlwdiCxZjDKRWszKGmwIHj1cYFvKFSIMTDj[YxteyCjc4Pld5Nm\CCjczDzeZBxemW|c3nvckBw\iClZXzsJIdzd3e2aDygTWM2OCB;IECuNlc2OSEQvF2u M4SwWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{exNVgxLz5{N{e3NVE5ODxxYU6=
CD34+ NXHzfYhxTnWwY4Tpc44h[XO|YYm= NUTGNmhKUW6qaXLpeIlwdiCxZjDKRWszKGixbX;kbY1meiCrbjDoeY1idiCFREO0L{Bk\WyuczDzdIls\WRiaX70c{BpfW2jbjD3bI9t\SCkbH;v[EBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGVRVy2rbnT1Z4VlKFOWQWStOUBxcG:|cHjvdplt[XSrb36gdJJmcW6ldXLheIVlKG[xcjC0OUBucW6|IH\vcIxwf2WmIHL5JGVRVyCjZHTpeIlwdiCvZXHzeZJm\CCjZoTldkAyPSCvaX7zJIJ6KE[DQ2OgZY5idHm|aYOsJGlEPTBiPTCwMlMxOiEQvF2u MoSzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MUe1N|MoRjJ2NEG3OVM{RC:jPh?=
HUO3 Mn3pSpVv[3Srb36gZZN{[Xl? MVu0JIRigXN? M17IfmlvcGmkaYTpc44hd2ZiaIXtZY4hT01vQ2PGMYlv\HWlZXSgdJJwdGmoZYLheIlwdiCrbjDoeY1idiCKVV:zJINmdGy|IHHzd4V{e2WmIHHzJHs{UF22aIntbYRqdmViaX7jc5Jxd3KjdHnvckBi\nSncjC0JIRigXNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiSVO1NEA:KDBwM{K0JO69VS5? NIfSbmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNEW5N|E5Oid-MUS1PVMyQDJ:L3G+
HU03 NXPNWJRtTnWwY4Tpc44h[XO|YYm= NIfSPFg4OiCqcoO= MmnpTY5pcWKrdHnvckBw\iCJTT3DV2YucW6mdXPl[EBpfW2jbjDIWVA{KGOnbHzzJJBzd2yrZnXyZZRqd25iYX\0[ZIhPzJiaILzJIJ6KFt|SG30bJlucWSrbnWgbY5kd3Kyb4LheIlwdiCjc4PhfUwhUUN3MDC9JFAvOzJ2IN88UU4> MlzkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzMEW3NVEoRjJzMUC1O|EyRC:jPh?=
BAF3 MWnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MWW3NkBpenN? MXPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDRkOgZ4VtdHNiZYjwdoV{e2mwZzDUSWwuUkGNMzDrbY5ie2ViYX\0[ZIhPzJiaILzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NCCLQ{WwJF0hOC53NzFOwG0v NXThXnUxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OlIzOzhpPkG5O|YzOjN6PD;hQi=>
T-cells MXLGeY5kfGmxbjDhd5NigQ>? M4L4Z|Mh\GG7cx?= NHXwRnhKdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjDv[kBKVDJvYXP0bZZifGWmIHHu[EBETDNiYX7kJGNFOjhiYX70bYJw\Hlvc4TpcZVt[XSnZDDtc5V{\SCFREStdI9{cXSrdnWgWEBk\WyuczDh[pRmeiB|IHThfZMh[nliWGTUJIF{e2G7LDDJR|UxKD1iMD62N{DPxE1w MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODR4MEi0Nkc,OzB2NkC4OFI9N2F-
NK92 M{HiSmZ2dmO2aX;uJIF{e2G7 MnXGNlAhdWmwcx?= M2rDVGlvcGmkaYTpc44hd2ZiVGnLNkBqdiCqdX3hckBPUzl{IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhUUxzMj3pcoR2[2WmIGPURXQ1KHCqb4PwbI9zgWyjdHnvckBqdmO3YnH0[YQh\m:{IEKwJI1qdnNiZn;scI94\WRiYomgTWwyOiClaHHscIVv\2ViZn;yJFQ2KG2rboOsJGVEPTBiPTCwMlcyKM7:TT6= M3ftelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkW5NlE1Lz5{M{[1PVIyPDxxYU6=
TF1 Mm\ZSpVv[3Srb36gZZN{[Xl? M37xN2lvcGmkaYTpc44hd2ZiSVyzMYlv\HWlZXSgdJJwdGmoZYLheIlwdiCxZjDUSlEh[2WubIOsJGlEPTBiPTCwMlgh|ryPLh?= NV;CS5BvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[5N|Q1PTdpPkG2PVM1PDV5PD;hQi=>
UT7 NEez[nZHfW6ldHnvckBie3OjeR?= MWDJcohq[mm2aX;uJI9nKEqDS{KgbY4hcHWvYX6gWXQ4KGOnbHzzJIF{e2W|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJGVRVy2|dHnteYxifGWmIGPURXQ2KHCqb4PwbI9zgWyjdHnvckBjgSCDbIDoZXNkemWnbjDhd5NigSxiSV7IJF0hOS5zMjFOwG0v NXLx[491RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zO|I3PTNpPkK2N|czPjV|PD;hQi=>
Ba/F3 MXHGeY5kfGmxbjDhd5NigQ>? MoS4OlAhdWmwcx?= MoL2TY5pcWKrdHnvckBw\iCWRVyt[pV{\WRiVGnLNkBmgHC{ZYPz[YQhcW5iQnGvSlMh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDTWGFVPSCyaH;zdIhwenmuYYTpc44h[W[2ZYKgOlAhdWmwczDifUBCdHCqYWPjdoVmdiCjc4PhfUwhUUN3MDC9JFEvOiEQvF2u NGjmV2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC4O|c2OCd-MkKwPFc4PTB:L3G+
T-cells NHPXVpVHfW6ldHnvckBie3OjeR?= MWq3NkBpenN? NYPIR|FlUW6qaXLpeIlwdiCxZjDKRWs{KGmwIILheEB{eGynbn;jfZRq[yCWIHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBKVC1{LXnu[JVk\WRiY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFnDOVAhRSBzLkKg{txONg>? M2qwVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMUO5OVc2Lz5|MEGzPVU4PTxxYU6=
SZ4 MlHFSpVv[3Srb36gZZN{[Xl? NH\nVFBKdmirYnn0bY9vKG:oIFrBT|MhcW5iaIXtZY4hW1p2IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBKVDJvc4TpcZVt[XSnZDDTWGFVPSCyaH;zdIhwenmuYYTpc44heHKnaX7jeYJifGWmIH\vdkAyKGi{IH\vcIxwf2WmIHL5JGlNOiC|dHnteYxifGmxbjDhcoQhdWWjc4Xy[YQh[W[2ZYKgNVUhdWmwczDifUBOW0RiYYPzZZktKEmFNUCgQUAyNjJzIN88UU4> MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODR4MEi0Nkc,OzB2NkC4OFI9N2F-
BAF3 M4ftWGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NWfkXnpjPzJiaILz MoCwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQV[zJINmdGy|IHX4dJJme3OrbnegWGVNNUqDS{Kgb4lv[XOnIHHmeIVzKDd{IHjyd{BjgSCjbHHtZZIh[my3ZTDhd5NigSxiSVO1NEA:KDFwNUe0JO69VS5? NFrk[II9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe2NlI{QCd-MUm3OlIzOzh:L3G+
HEL NYPCRlJtTnWwY4Tpc44h[XO|YYm= MoWwNUBpeg>? NV\UdllzUW6qaXLpeIlwdiCxZjDKRWszKFZ4MUfGJI12fGGwdDDpckBpfW2jbjDISWwh[2WubIOgZYZ1\XJiMTDodkwhUUN3MDC9JFQvPzJ2IN88UU4> M3fvTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{exNVgxLz5{N{e3NVE5ODxxYU6=
Jurkat MkLjSpVv[3Srb36gZZN{[Xl? NF;jVJUzPCCqcoO= MnLSTY5pcWKrdHnvckBw\iCjboTpMWNFOy:jboTpMWNFOjhvaX7keYNm\CCLTEKgdJJw\HWldHnvckBqdiCqdX3hckBLfXKtYYSgZ4VtdHNiYX\0[ZIhOjRiaILzJIJ6KHOlaX70bYxt[XSrb36gZ492dnSrbnesJGlEPTBiPTC3Mlg1KM7:TT6= NXS3SW5XRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUS1PVMyQDJpPkG0OVk{OTh{PD;hQi=>
YT NFjEV|JHfW6ldHnvckBie3OjeR?= MWizNEBv\y:vbB?= MUfJcohq[mm2aX;uJI9nKEmOMj3pcoR2[2WmIFrBT|MheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJHlVKGOnbHzzJIF1KDNyIH7nM41tKGK7IHntcZVvd2Kub4T0bY5oKGGwYXz5d4l{ MmP3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTR3OUOxPFIoRjF2NUmzNVgzRC:jPh?=
YT M3rLdmZ2dmO2aX;uJIF{e2G7 NWHjbHA4OzBibnevcYw> MW\Jcohq[mm2aX;uJI9nKEmOMj3pcoR2[2WmIGPURXQ2SSCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hYVRiY3XscJMh[XRiM{CgcocwdWxiYomgbY1ufW6xYnzveJRqdmdiYX7hcJl{cXN? M3P3ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2NUmzNVgzLz5zNEW5N|E5OjxxYU6=
YT M2ewTWZ2dmO2aX;uJIF{e2G7 MnG2N|AhdmdxbXy= NVPBUm9vUW6qaXLpeIlwdiCxZjDJUFIucW6mdXPl[EBUXEGWNVKgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIGnUJINmdGy|IHH0JFMxKG6pL33sJIJ6KGmvbYXuc4Jtd3S2aX7nJIFv[Wy7c3nz M4fER|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2NUmzNVgzLz5zNEW5N|E5OjxxYU6=
NK-cells M3rVUGludXWwb4P1dJBz\XO|aY\lJIF{e2G7 NYjKSXVjOSC2bzC1JI1oN2up MXq0JJdm\Wu| NIraUJFKdW23bn;zeZBxemW|c3n2[UBi[3Srdnn0fUBqdiCwYXn2[UBkgW6xbX;s[5V{KG2xbnvlfUBie3Onc4Pl[EBieyCnZn\lZ5Qhd25iQ1SzMWNFOTZtIF7LJINmdGy|IHH0JFEhfG9iNTDt[{9s\yxicH:g[o9zKDRid3Xlb5M> NVXC[mpVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUS1PVMyQDJpPkG0OVk{OTh{PD;hQi=>
T-cells NUfMW4lCTnWwY4Tpc44h[XO|YYm= NXnkZYFwPSC2bzC1NFAhdk1? NIXGTWIyKGi{ MVXJcohq[mm2aX;uJI9nKEmOMj3pcoR2[2WmIGP0ZZQ2KHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBETDRtIGSgZ4VtdHNiYYSgOUB1dyB3MECgcm0h[W[2ZYKgNUBpeiCkeTDX[ZN1\XKwIHLsc5Q> MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTB3M{e1Okc,OTlyNUO3OVY9N2F-
SUM149PT MVLGeY5kfGmxbjDhd5NigQ>? NEjpXHI{KHWP MVexOkBpenN? MXzJcoR2[3Srb36gc4YhWFSSTk[gbY4hcHWvYX6gV3VOOTR7UGSgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCVVFHUN{BxcG:|cHjvdplt[XSrb36gZZQhOyC3TTDh[pRmeiBzNjDodpMh[nliV3XzeIVzdiCkbH;0eIlv\yCjbnHsfZNqeyCrbjDwdoV{\W6lZTDv[kBx\XK4YX7h[IF1\Q>? M1fUPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUe4NVEzLz5{NEm3PFEyOjxxYU6=
Hs578T Ml;hSpVv[3Srb36gZZN{[Xl? M2PEVVMhfU1? MU[xOkBpenN? NHu4UY1KdmS3Y4Tpc44hd2ZiUGTQUlYhcW5iaIXtZY4hUHN3N{jUJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiU2TBWFMheGixc4Doc5J6dGG2aX;uJIF1KDNidV2gZYZ1\XJiMU[gbJJ{KGK7IGfld5Rmem5iYnzveJRqdmdiYX7hcJl{cXNiaX6gdJJme2WwY3Wgc4YheGW{dnHuZYRifGV? MkfpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7N{ixNVIoRjJ2OUe4NVEzRC:jPh?=
T-cells NUD0fZVRTnWwY4Tpc44h[XO|YYm= NWjzT|I4PTBidH:gN|AxKG6P MnLVNUBpeg>? NWGwUZhwUW6qaXLpeIlwdiCxZjDKRWsyN0qDS{OgbY4hcHWvYX6gR2Q1KHCxc3n0bZZmKFRiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBKVDRvc4TpcZVt[XSnZDDTWGFVPiCyaH;zdIhwenmuYYTpc44h[XRiNUCgeI8hOzByIH7NJJBz\WmwY4XiZZRm\CCob4KgNUBpeiCob3zsc5dm\CCkeTDJUE01KHO2aX31cIF1cW:wIH3lZZN2emWmIHHmeIVzKDNyIH3pcpMh[nliaX3teY5w[myxdDDhcoFtgXOrcx?= M1XudlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OEWyNFY5Lz5{OUi1NlA3QDxxYU6=
T-cells M2C1T2Z2dmO2aX;uJIF{e2G7 NVi1XIpvPTBidH:gN|AxKG6P M4XwelEhcHJ? MlvoTY5pcWKrdHnvckBw\iCMQVuxM2pCUzNiaX6gbJVu[W5iQ1S0JJBwe2m2aY\lJHQh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDJUFIue3SrbYXsZZRm\CCVVFHUOUBxcG:|cHjvdplt[XSrb36gZZQhXHm{LU[5OUBz\XOrZIXlJIF1KDVyIITvJFMxOCCwTTDwdoVqdmO3YnH0[YQh\m:{IEGgbJIh\m:ubH;3[YQh[nliSVytNkB{fGmvdXzheIlwdiCvZXHzeZJm\CCjZoTldkA{OCCvaX7zJIJ6KGmvbYXuc4Jtd3RiYX7hcJl{cXN? Mn;XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl6NUKwOlgoRjJ7OEWyNFY5RC:jPh?=
T-cells M2Lh[2Z2dmO2aX;uJIF{e2G7 NIHRWZg,OzByIH7N M3P0N|EhcHJ? M1PEV2lvcGmkaYTpc44hd2ZiSlHLNU9LSUt{L2TZT|IhcW5iaIXtZY4hS0R2IIDvd4l1cX[nIGSgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCLTE[td5RqdXWuYYTl[EBUXEGWMzDwbI9{eGixconsZZRqd25iYYSgQlMxOCCwTTDwdoVqdmO3YnH0[YQh\m:{IEGgbJIh\m:ubH;3[YQh[nliSVytOkB{fGmvdXzheIlwdiCvZXHzeZJm\CCjZoTldkA{OCCvaX7zJIJ6KGmvbYXuc4Jtd3RiYX7hcJl{cXN? NUDnd|RURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm4OVIxPjhpPkK5PFUzODZ6PD;hQi=>
TALL-1 M3fhVWZ2dmO2aX;uJIF{e2G7 MkTZNUB2VQ>? NI\kcmM{KGi{cx?= NUXDfoc4UW6qaXLpeIlwdiCxZjDKRWs{KGmwIHj1cYFvKFSDTFytNUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFnMMVIhcW6mdXPl[EBUXEGWNTDwbI9{eGixconsZZRqd25iYYSgNUB2VSCycnXpcoN2[mG2ZXSg[o9zKDNiaILzJIZwdGyxd3XkJIJ6KEmOLUKgbY5lfWO2aX;uJI1m[XO3cnXkJIFnfGW{IEOwJI1qdnNiYomgbY1ufW6xYnzveJRqdmd? M1HLTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkW4OVIyLz5{NkK1PFUzOTxxYU6=
BA/F3 M17memZ2dmO2aX;uJIF{e2G7 NGPm[VI{ODBibl2= MYqzJIhzew>? MnfzTY5pcWKrdHnvckBw\iCMQVuzJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW|c3XkJIlvKG2xdYPlJGJCN0Z|IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDv[kBUXEGWNTDwbI9{eGixconsZZRqd25iYYSgN|AxKG6PIHHmeIVzKDNiaILzJIJ6KGmvbYXuc4Jtd3S2aX7nJIFv[Wy7c3nz MnrTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{NUi1NlEoRjJ4MkW4OVIyRC:jPh?=
OCL-AML5 MWDGeY5kfGmxbjDhd5NigQ>? NX7xbpI5OSC3TR?= MWSzJIhzew>? NFvtdGVKdmirYnn0bY9vKG:oIFrBT|IhcW5iaIXtZY4hV0OOLVHNUFUh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDHUU1EW0ZiaX7keYNm\CCVVFHUOUBxcG:|cHjvdplt[XSrb36gZZQhOSC3TTDwdoVqdmO3YnH0[YQh\m:{IEOgbJJ{KG[xbHzve4VlKGK7IFfNMWNUTiCrbnT1Z5Rqd25ibXXhd5Vz\WRiYX\0[ZIhOzBibXnud{BjgSCrbX31co9jdG:2dHnu[y=> MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ3OEWyNUc,OjZ{NUi1NlE9N2F-
BA/F3 NVu5[YhRSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NImwOHg4OiCqcoO= Mn6zRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO|aX7nJHRGVC2MQVuzJIFnfGW{IEeyJIhzeyCkeTDj[YxtKHSrdHXyJIdtdyCjc4PhfS=> Ml:wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{NUi1NlEoRjJ4MkW4OVIyRC:jPh?=
BA/F3 NXvmRW9yTnWwY4Tpc44h[XO|YYm= MlW5NUB2VQ>? NVXObZU6OyCqcoO= NF;k[mZKdmirYnn0bY9vKG:oIFrBT|MhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5ibX;1d4UhSkFxRkOgZ4VtdHNiYYSgNUB2VSCycnXpcoN2[mG2ZXSg[o9zKDNiaILzJIZwdGyxd3XkJIJ6KHC3bHzkc5dvKHerdHigd5Rz\XC2YY\p[IlvKGKnYXTzJIJ6KGmvbYXuc4Jtd3S2aX7nJIFv[Wy7c3nz M{KySlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkW4OVIyLz5{NkK1PFUzOTxxYU6=
Huh7 M1v1VGZ2dmO2aX;uJIF{e2G7 NEjQUmcyOCC3TR?= NEHRPWo{OCCvaX7z MYTJcohq[mm2aX;uJI9nKFS7a{KgbY4hcHWvYX6gTJVpPyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gTWZP[WyyaHG1MYlv\HWlZXSgV3RCXDNicHjvd5Bpd3K7bHH0bY9vKGG2IEGwJJVOKHC{ZT3pcoN2[mG2ZXSg[o9zKDNyIH3pcpMh[mWob4LlJGlHVmGucHjhOUB{fGmvdXzheIlwdiCob4KgN|AhdWmwczDtbY5{KGK7IHntcZVvd2Kub4T0bY5o MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ|MUG1PUc,OjZ{M{GxOVk9N2F-
Huh7 MmLHSpVv[3Srb36gZZN{[Xl? NYWycY1ZOTBidV2= M1PDflMxKG2rboO= M2XDWWlvcGmkaYTpc44hd2ZiVInrNkBqdiCqdX3hckBJfWh5IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDv[kBj[XOjbDDs[ZZmdCCVVFHUN{BxcG:|cHjvdplt[XSrb36gZZQhOTBidV2gZYZ1\XJiM{CgcYlveyCkeTDpcY12dm:kbH;0eIlv\w>? MnLPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{M{GxOVkoRjJ4MkOxNVU6RC:jPh?=
Huh7 M2j2TGZ2dmO2aX;uJIF{e2G7 NY\MNWRxOSC3TR?= MX[zNEBucW6| MUPJcohq[mm2aX;uJI9nKFS7a{KgbY4hcHWvYX6gTJVpPyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gTWZP[WyyaHG1MYlv\HWlZXSgV3RCXDNicHjvd5Bpd3K7bHH0bY9vKGG2IEGgeW0heHKnLXnuZ5Vj[XSnZDDmc5IhOzBibXnud{Bj\W[xcnWgTWZP[WyyaHG1JJN1cW23bHH0bY9vKG[xcjCzNEBucW6|IH3pcpMh[nliaX3teY5w[myxdITpcoc> MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ|MUG1PUc,OjZ{M{GxOVk9N2F-
Assay
Methods Test Index PMID
Western blot JAK3 / STAT5 / p-STAT5 ; LMP1 / EBNA1 / BZLF1 ; JAK3 / p-JAK3 / STAT3 27732937 26082451
Growth inhibition assay Cell number 27732937
In vivo In a murine model of heterotopic heart transplantation (DBA2 donor heart into C57/BL6 host), CP-690550 results in a dose-dependent increase in survival of transplanted hearts.The EC50 (drug concentration in blood at which 50% of mice will maintain their graft for >28 days) to be ~60 ng/mL.CP-690550 prevents rejection of allogeneic kidneys in nonhuman primate (NHPs, macaca fascicularis) (MST of 62 and 83 days for the 50 to 100 ng/ml groups and 200 to 400 ng/ml groups, respectively). [1] Mice chronically dosed with CP-690550 (1.5-15 mg/kg/day) demonstrates dose and time-dependent alterations in lymphocyte subsets when examined by flow cytometry. The most dramatic change observed is a 96% reduction in splenic NK1.1+TCRb-cell numbers following 21 days of treatment. Delayed-type hypersensitivity (DTH) responses in sensitized mice are reduced in a dose-dependent manner following treatment with CP-690550 (1.87–30 mg/kg, s.c.). Extended survival of neonatal Balb/c hearts implanted into the ear pinna of MHC mismatched C3H/HEN mice is observed with CP-690550 monotherapy (10–30 mg/kg/day), but improved upon combination with cyclosporin (10 mg/kg/day). [2]

Protocol (from reference)

Kinase Assay:

[1]

  • JAK3 Kinase Assay:

    A fragment encoding the catalytic domain of human JAK3 (785aa to 1125aa, JH1 catalytic domain) is amplified by PCR from the full length cDNA and cloned into the EcoRI site of the baculovirus transfer vector pVL1393. Recombinant baculovirus is used to infect Sf9 (Spodoptera frugipedra) cells and recombinant GSTJAK3 fusion protein is isolated on glutathione sepharose. The fusion protein is eluted with reduced glutathione and stored in buffer containing 50 mM Tris, pH 7.5, 10 mM DTT and 10% glycerol. JAK3 kinase activity is measured by ELISA as follows: Plates are coated overnight with a random L-glutamic acid and tyrosine co-polymer (4:1) (100 ug/mL). The plates are washed and recombinant JAK3 JH1:GST (100 ng/well) with or without inhibitors is incubated at room temperature for 30 minutes, after which HRP-conjugated PY20 anti-phosphotyrosine antibody (ICN) is added and developed by TMB (3,3',5,5'-tetramethylbenzidine). Other kinases (Table 1) are produced in E. coli or in insect cells, depending upon what is found to be optimal for the given kinase. The catalytic activity of tyrosine kinases is easured using the aftorementioned ELISA, whereas serine/threonine kinases are assayed using radioactive enzyme assays.

Cell Research:

[1]

  • Cell lines: Human T blasts cell
  • Concentrations: 0-4000 nM
  • Incubation Time: 4 days
  • Method:

    To measure IL-2-dependent proliferation, isolated lymphocytes are resuspended to a cell density of 1-2 × 106/mL in complete RPMI medium (RPMI 1640 containing 10% (w/v) fetal calf serum (FCS), 1%(w/v) penicillin and treptomycin).Phytohemagluttinin (PHA) is added to a final concentration of 10mg/mL, and the culture incubated for 3 days at 37 °C in a humidified 5% (v/v) CO2 incubator to upregulate IL-2R and JAK3 expression. IL-2 (200U/mL), with or without CP-690,550 is then added and the cells are incubated for 72 hours at 37 °C in a humidified 5% (v/v) CO2 incubator, after which 50 mL of 3H-thymidine (5mCi/mL) is added. The plates are incubated for an additional 18 hours, harvested with a 96-well harvester, and counted on a scintillation counter. HUO3 cells are maintained in culture with granulocyte-macrophage colony stimulating factor and human foreskin fibroblasts are maintained in culture with 10% fetal calf serum. CP-690550 is added to freshly plated cells and cultured for 4 days. 3Hthymidine is added during the last 18 hours of the culture period.

Animal Research:

[1]

  • Animal Models: DBA/2 and C57/BL6 mice
  • Dosages: 0-136 ng/mL
  • Administration: Administered via osmotic minipump infusion

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.

5mg/mL

Chemical Information

Molecular Weight 312.37
Formula

C16H20N6O

CAS No. 477600-75-2
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05082428 Not yet recruiting -- Ulcerative Colitis Pfizer December 1 2021 --
NCT05087589 Recruiting Drug: Tofacitinib Primary Sjögren''s Syndrome Peking University People''s Hospital November 18 2021 Phase 2
NCT04768504 Recruiting Drug: Tofacitinib 10 mg Immune-Mediated Colitis Khashayar Esfahani|Sir Mortimer B. Davis - Jewish General Hospital November 15 2021 Phase 2
NCT04624230 Recruiting Drug: tofacitinib Ulcerative Colitis Pfizer August 12 2021 Phase 3
NCT04496960 Recruiting Drug: tofacitinib|Other: Placebo Sjogren''s Syndrome National Institute of Dental and Craniofacial Research (NIDCR)|National Institutes of Health Clinical Center (CC) May 18 2021 Phase 1|Phase 2
NCT04424303 Recruiting Drug: Tofacitinib Ulcerative Colitis Pfizer December 7 2020 --

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
I was just wondering what the main differences between S2789 and S5001?

Answer:
S2789(Tofacitinib (CP-690550)) is the base form of S5001 (Tofacitinib (CP-690550) Citrate). The biological activity of these two compounds are same. The S5001 (Tofacitinib (CP-690550) Citrate) is more suitable for oral administration.

Tags: buy Tofacitinib (CP-690550) | Tofacitinib (CP-690550) supplier | purchase Tofacitinib (CP-690550) | Tofacitinib (CP-690550) cost | Tofacitinib (CP-690550) manufacturer | order Tofacitinib (CP-690550) | Tofacitinib (CP-690550) distributor